268 related articles for article (PubMed ID: 12228849)
1. Renin-angiotensin system antagonism and lipid-lowering therapy in cardiovascular risk management.
Chiong JR; Miller AB
J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):96-102. PubMed ID: 12228849
[TBL] [Abstract][Full Text] [Related]
2. Statins: another class of antihypertensive agents?
Milionis HJ; Liberopoulos EN; Achimastos A; Elisaf MS; Mikhailidis DP
J Hum Hypertens; 2006 May; 20(5):320-35. PubMed ID: 16511505
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cardiovascular events in patients with angiographically documented coronary narrowing with combined renin-angiotensin system inhibitor plus statin versus renin-angiotensin system inhibitor alone versus statin alone (from the Japanese Coronary Artery Disease Study).
Fujita M; Yamazaki T; Hayashi D; Kohro T; Okada Y; Nagai R;
Am J Cardiol; 2007 Dec; 100(12):1750-3. PubMed ID: 18082520
[TBL] [Abstract][Full Text] [Related]
4. HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?
März W; Köenig W
J Cardiovasc Risk; 2003 Jun; 10(3):169-79. PubMed ID: 12775949
[TBL] [Abstract][Full Text] [Related]
5. Optimal medical management of peripheral arterial disease.
Rice TW; Lumsden AB
Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
[TBL] [Abstract][Full Text] [Related]
6. Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?
Comparato C; Altana C; Bellosta S; Baetta R; Paoletti R; Corsini A
Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):328-43. PubMed ID: 11887430
[TBL] [Abstract][Full Text] [Related]
7. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease.
Packard C
Atheroscler Suppl; 2006 Apr; 7(1):21-9. PubMed ID: 16504600
[TBL] [Abstract][Full Text] [Related]
8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
9. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions.
Mason RP; Walter MF; Day CA; Jacob RF
Am J Cardiol; 2005 Sep; 96(5A):11F-23F. PubMed ID: 16126019
[TBL] [Abstract][Full Text] [Related]
10. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
11. Lipid lowering therapy in atherosclerosis.
Aikawa M; Libby P
Semin Vasc Med; 2004 Nov; 4(4):357-66. PubMed ID: 15861316
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes.
Macfarlane DP; Paterson KR; Fisher M
Diabetes Obes Metab; 2008 Jul; 10(7):533-44. PubMed ID: 18248492
[TBL] [Abstract][Full Text] [Related]
13. Statins and their role in vascular protection.
Mason JC
Clin Sci (Lond); 2003 Sep; 105(3):251-66. PubMed ID: 12793855
[TBL] [Abstract][Full Text] [Related]
14. Statins and cardioprotection--more than just lipid lowering?
Ludman A; Venugopal V; Yellon DM; Hausenloy DJ
Pharmacol Ther; 2009 Apr; 122(1):30-43. PubMed ID: 19318042
[TBL] [Abstract][Full Text] [Related]
15. [Statins and their pleiotropic effects].
Galus R; Zandecki Ł; Jóźwiak J; Włodarski K
Pol Merkur Lekarski; 2008 Jun; 24(144):545-8. PubMed ID: 18702340
[TBL] [Abstract][Full Text] [Related]
16. Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins.
Wheeler DC
J Nephrol; 2001; 14 Suppl 4():S70-5. PubMed ID: 11798150
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effects and cholesterol-lowering therapy.
Shaw SM; Fildes JE; Yonan N; Williams SG
Cardiology; 2009; 112(1):4-12. PubMed ID: 18577880
[TBL] [Abstract][Full Text] [Related]
18. [Vasoprotective effects of statins and angiotensin II blockers in atherothrombosis].
Egido J; Ruiz-Ortega M; Muñoz-García B; Martín-Ventura JL; Blanco-Colio LM
Nefrologia; 2005; 25 Suppl 2():117-28. PubMed ID: 16050414
[TBL] [Abstract][Full Text] [Related]
19. Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients?
Steffens S; Mach F
Nat Clin Pract Nephrol; 2006 Jul; 2(7):378-87. PubMed ID: 16932466
[TBL] [Abstract][Full Text] [Related]
20. Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease.
Ferdinand KC
Curr Med Res Opin; 2005 Jul; 21(7):1091-7. PubMed ID: 16004678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
